About Contact Us Careers

Nontuberculous Mycobacterium Treatment Market Trends

Request Free Sample Copy

Report ID: 4072
Published Date: Aug 16, 2024
Report Format: PDF, PPT

Buy Now

Nontuberculous Mycobacterium Treatment Market Trends

Growth Drivers

Increasing Prevalence of Nontuberculous Mycobacterium Infection
Rising Geriatric Population Globally

Challenges

High Cost of Treatment
Unavailability of Advanced Treatment Methods in Developing Regions

Nontuberculous Mycobacterium Treatment Market: Key Insights

Base Year	2023
Forecast Year	2024–2036
CAGR	2.6%
Base Year Market Size (2023)	USD 9.11 billion
Forecast Year Market Size (2036)	USD 12.72 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Nontuberculous Mycobacterium Treatment Market Size & Share | Growth Trends 2036

Author Credits: Radhika Pawar

Report ID: 4072
Published Date: Aug 16, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nontuberculous mycobacterium treatment is estimated at USD 9.3 billion.

Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.11 billion in 2023 and is likely to reach USD 12.72 billion by 2036, registering around 2.6% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of nontuberculous mycobacterium infections will boost the market growth.

Asia Pacific industry is predicted to hold largest revenue share by 2036, on the back of improving healthcare infrastructure, along with growing geriatric population in the region.

The major players in the market are Atara Biotherapeutics, Inc., Kadmon Holdings, Inc., Beyond Air Inc., Savara Inc., RedHill Biopharma Ltd., Insmed Inc., Novartis AG, GlaxoSmithKline plc, and TFF Pharmaceuticals, Inc.

Inquiry Before Buying Request Free Sample